NASDAQ: GNLXGenelux Corp Stock
$2.70+0.07 (+2.66%)
Updated Apr 21, 2025
GNLX Price
$2.70
Fair Value Price
$0.21
Market Cap
$93.43M
52 Week Low
$1.60
52 Week High
$5.89
P/E
-2.84x
P/B
3.56x
P/S
9,277.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.00k
Earnings
-$29.87M
Gross Margin
100%
Operating Margin
-373,362.5%
Profit Margin
-373,362.5%
Debt to Equity
0.32
Operating Cash Flow
-$21M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNLX Overview
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GNLX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GNLX
Ranked#156 of 462
Ranked#156 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important GNLX news, forecast changes, insider trades & much more!
GNLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNLX ($2.70) is overvalued by 1,169.37% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNLX ($2.70) is not significantly undervalued (1,169.37%) relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNLX due diligence checks available for Premium users.
Valuation
GNLX fair value
Fair Value of GNLX stock based on Discounted Cash Flow (DCF)
Price
$2.70
Fair Value
$0.21
Overvalued by
1,169.37%
GNLX ($2.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNLX ($2.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.84x
Industry
-184.27x
Market
27.14x
GNLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.56x
Industry
4.04x
GNLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNLX's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.0M
Profit Margin
0%
GNLX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GNLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$34.7M
Liabilities
$8.4M
Debt to equity
0.32
GNLX's short-term assets ($31.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNLX's short-term assets ($31.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$6.7M
Financing
$91.0k
GNLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNLX vs Biotech Stocks
Genelux Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.